{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:31:55Z","timestamp":1789565515110,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.mayocp.2022.11.017","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T06:33:49Z","timestamp":1675233229000},"page":"350-351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["ACEI and ARB \u2014 Each Unique RAAS Inhibitors"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1746-4050","authenticated-orcid":false,"given":"Martin H.","family":"Strauss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0306-7887","authenticated-orcid":false,"given":"Alistair S.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5949-5018","authenticated-orcid":false,"given":"Krzysztof","family":"Narkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.mayocp.2022.11.017_bib1","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.mayocp.2022.06.036","article-title":"Effect of the renin-angiotensin system inhibitors on inflammatory markers: a systematic review and meta-analysis of randomized controlled trials","volume":"97","author":"Awad","year":"2022","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.mayocp.2022.11.017_bib2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ajh\/hpab108","article-title":"Renin angiotensin blockers and cardiac protection: from basis to clinical trials","volume":"35","author":"Levy","year":"2022","journal-title":"Am J Hypertens"},{"issue":"8","key":"10.1016\/j.mayocp.2022.11.017_bib3","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1161\/CIRCULATIONAHA.105.594986","article-title":"Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox","volume":"114","author":"Strauss","year":"2006","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.mayocp.2022.11.017_bib4","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients","volume":"33","author":"van Vark","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mayocp.2022.11.017_bib5","doi-asserted-by":"crossref","unstructured":"Turnbull F, Neal B, Pfeffer M, et\u00a0al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system [published correction appears in J Hypertens. 2007;25(7):1524]. J Hypertens. 2007;25(5):951-958.","DOI":"10.1097\/HJH.0b013e3280bad9b4"},{"issue":"1","key":"10.1016\/j.mayocp.2022.11.017_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.mayocp.2015.10.019","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials","volume":"91","author":"Bangalore","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"22","key":"10.1016\/j.mayocp.2022.11.017_bib7","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/CIRCULATIONAHA.117.026112","article-title":"Angiotensin receptor blockers do not reduce risk of myocardial infarction, cardiovascular death, or total mortality: further evidence for the ARB-MI paradox","volume":"135","author":"Strauss","year":"2017","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.mayocp.2022.11.017_bib8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/CIRCULATIONAHA.121.057835","article-title":"Why are we still prescribing angiotensin-converting enzyme inhibitors?","volume":"145","author":"Messerli","year":"2022","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.mayocp.2022.11.017_bib9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/HYPERTENSIONAHA.120.16667","article-title":"Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study","volume":"78","author":"Chen","year":"2021","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.mayocp.2022.11.017_bib10","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.pmrj.2012.07.002","article-title":"Propensity scores: uses and limitations","volume":"4","author":"Sainani","year":"2012","journal-title":"PM R"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561962200667X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561962200667X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:39:48Z","timestamp":1758418788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002561962200667X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S002561962200667X"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.11.017","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ACEI and ARB \u2014 Each Unique RAAS Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}